HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (4- ((2- ((cyclopropylcarbonyl)amino)imidazo(1,2- a)pyridin- 6- yl)oxy)- 3- fluorophenyl)- 6- methyl- 2- oxo- 1- phenyl- 1,2- dihydropyridine- 3- carboxamide

structure in first source

Also Known As:

T-1840383

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198

Experts

1.	Awazu, Yoshiko: 1 article (06/2013)
2.	Hori, Akira: 1 article (06/2013)
3.	Imamura, Shinichi: 1 article (06/2013)
4.	Iwata, Hidehisa: 1 article (06/2013)
5.	Kakoi, Yuichi: 1 article (06/2013)
6.	Miki, Hiroshi: 1 article (06/2013)
7.	Miyamoto, Naoki: 1 article (06/2013)
8.	Mizutani, Akio: 1 article (06/2013)
9.	Nakamura, Kazuhide: 1 article (06/2013)
10.	Yamasaki, Seiji: 1 article (06/2013)

Related Diseases

1.

Neoplasms (Cancer)

06/01/2013 - "These results suggest that the efficacy of T-1840383 is produced by direct effects on tumor cell growth and by an antiangiogenic mechanism. "
06/01/2013 - "Furthermore, T-1840383 showed profound antitumor activity in a gastric tumor peritoneal dissemination model. "
06/01/2013 - "Following oral administration, T-1840383 showed potent antitumor efficacy in a wide variety of human tumor xenograft mouse models, along with reduction of c-Met phosphorylation levels and microvessel density within tumor xenografts. "
06/01/2013 - "T-1840383 inhibited HGF-induced c-Met phosphorylation and VEGF-induced VEGFR-2 phosphorylation in cancer epithelial cells and vascular endothelial cells, respectively. "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
2.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)

Related Therapies and Procedures

1.	Oral Administration